Halozyme Therapeutics, Inc.
HALO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001159036
In the last 90 days, Halozyme Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 673 institutions reported holding it in 13F filings for Q2 2026, worth $9.62B in total; no superinvestor holds it.
Holders of 5% or more of HALO
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Halozyme Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 10.20%12.6M shares | −2.90 ppfrom 13.10% | Apr 28, 20252 filings | Jul 17, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
4 Schedule 13D and 13G filings on Halozyme Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 20269:33 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Jul 17, 20257:54 PM ET | BlackRock, Inc. | 13G/A | 10.20%12.6M shares | −2.90 ppfrom 13.10% | Jun 30, 2025 | SEC |
| May 13, 202511:18 AM ET | State Street Corp | 13G | 4.90%6.05M shares | NewBelow 5% | Mar 31, 2025 | SEC |
| Apr 28, 20255:18 PM ET | BlackRock, Inc. | 13G/A | 13.10%16.1M shares | – | Mar 31, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Halozyme Therapeutics, Inc. shares.
No Form 144 notices for Halozyme Therapeutics, Inc. are on file.